Playing the Devil’s Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? – ie Strategies to Revert Resistance to mTOR Inhibitors-Reference-Cited by-同舟云学术

Playing the Devil’s Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? – ie Strategies to Revert Resistance to mTOR Inhibitors

Published:2021-10 Issue: Volume:Volume 13 Page:7623-7636
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Pezzicoli Gaetano,Filoni Elisabetta,Gernone Angela,Cosmai Laura,Rizzo Mimma,Porta Camillo^ORCID

Publisher

Informa UK Limited

Subject

Oncology

Reference100 articles.

1. Targeting mammalian target of rapamycin (mTOR) for health and diseases

2. TOR Signaling in Growth and Metabolism

3. Targeting mTOR in renal cell carcinoma

4. mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets

5. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment options in the advanced and recurrent setting for endometrial cancer: an update;Expert Review of Anticancer Therapy;2024-06-24

2. Differential expression analysis identifies a prognostically significant extracellular matrix–enriched gene signature in hyaluronan-positive clear cell renal cell carcinoma;Scientific Reports;2024-05-09

3. Analysis of HIF-1α expression and genetic polymorphisms in human clear cell renal cell carcinoma;Pathology and Oncology Research;2024-01-11

4. Genomic Profiling and Molecular Characterization of Clear Cell Renal Cell Carcinoma;Current Oncology;2023-10-20

5. Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing;Lung Cancer;2023-04